Nan Shan Life Insurance Co. Ltd. bought a new position in Versigent (NYSE:VGNT - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 128,541 shares of the company's stock, valued at approximately $5,400,000. Nan Shan Life Insurance Co. Ltd. owned 0.18% of Versigent at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Ancora Advisors LLC purchased a new stake in shares of Versigent during the 2nd quarter valued at about $4,197,000. Wellington Management Group LLP purchased a new position in Versigent in the 2nd quarter worth approximately $940,000. Finally, Kintegral Advisory LLC acquired a new stake in Versigent in the second quarter valued at approximately $224,000.
Versigent Price Performance
Shares of VGNT stock opened at $46.22 on Wednesday. The business's fifty day moving average is $43.36. The firm has a market cap of $3.27 billion and a price-to-earnings ratio of 24.07. Versigent has a 1-year low of $26.34 and a 1-year high of $50.88. The company has a debt-to-equity ratio of 7.29, a quick ratio of 1.09 and a current ratio of 1.40.
Versigent (NYSE:VGNT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.58 by $0.34. The company had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.29 billion. On average, sell-side analysts expect that Versigent will post 7.23 EPS for the current year.
Versigent Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Stockholders of record on Friday, September 4th will be given a $0.13 dividend. The ex-dividend date is Friday, September 4th. This represents a $0.52 annualized dividend and a dividend yield of 1.1%.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on VGNT. Fox Advisors lowered shares of Versigent from an "overweight" rating to an "equal weight" rating in a research note on Wednesday, August 5th. Morgan Stanley initiated coverage on shares of Versigent in a research note on Friday, May 8th. They set an "overweight" rating and a $51.00 price target on the stock. UBS Group decreased their price objective on shares of Versigent from $58.00 to $55.00 and set a "buy" rating for the company in a research report on Thursday, July 9th. Wells Fargo & Company raised their target price on Versigent from $48.00 to $56.00 and gave the company an "overweight" rating in a research note on Wednesday, August 5th. Finally, Evercore reissued an "outperform" rating and issued a $65.00 price target on shares of Versigent in a report on Monday, August 10th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $54.00.
Get Our Latest Stock Analysis on Versigent
About Versigent
(
Free Report)
Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.
Further Reading
Want to see what other hedge funds are holding VGNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versigent (NYSE:VGNT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Versigent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Versigent wasn't on the list.
While Versigent currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.